GT201300153A - Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina - Google Patents
Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diaminaInfo
- Publication number
- GT201300153A GT201300153A GT201300153A GT201300153A GT201300153A GT 201300153 A GT201300153 A GT 201300153A GT 201300153 A GT201300153 A GT 201300153A GT 201300153 A GT201300153 A GT 201300153A GT 201300153 A GT201300153 A GT 201300153A
- Authority
- GT
- Guatemala
- Prior art keywords
- penim
- isopropoxi
- pyrimidim
- propan
- piperidin
- Prior art date
Links
- -1 PROPAN-2-SULFONYL Chemical class 0.000 title abstract 2
- 239000013078 crystal Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201061424194P | 2010-12-17 | 2010-12-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT201300153A true GT201300153A (es) | 2014-06-09 |
Family
ID=45464892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT201300153A GT201300153A (es) | 2010-12-17 | 2013-06-17 | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina |
Country Status (36)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS57771B1 (sr) * | 2010-12-17 | 2018-12-31 | Novartis Ag | Kristalni oblici 5-hloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina |
| BR112015010221B1 (pt) | 2012-11-06 | 2022-09-13 | Shanghai Fochon Pharmaceutical Co., Ltd. | Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
| CN105294649B (zh) * | 2014-07-30 | 2019-05-14 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| CN105294650A (zh) * | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| EP3760618A1 (en) | 2014-10-21 | 2021-01-06 | ARIAD Pharmaceuticals, Inc. | Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl]pyrimidine-2,4-diamine |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| CN105601614A (zh) * | 2014-11-21 | 2016-05-25 | 奥浦顿（上海）医药科技有限公司 | 一种色瑞替尼晶型及其制备方法 |
| WO2016082795A1 (zh) * | 2014-11-28 | 2016-06-02 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型i及其制备方法 |
| CN105622577A (zh) * | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| WO2016108123A2 (en) * | 2014-12-17 | 2016-07-07 | Dr. Reddy’S Laboratories Limited | Pure amorphous and amorphous solid dispersion of ceritinib |
| WO2016098042A1 (en) * | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| EP3328848A1 (en) | 2015-07-28 | 2018-06-06 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) * | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| WO2017152858A1 (zh) * | 2016-03-11 | 2017-09-14 | 苏州晶云药物科技有限公司 | 色瑞替尼的晶型及其制备方法 |
| US10604505B2 (en) | 2016-03-15 | 2020-03-31 | Natco Pharma Limited | Modified process for the preparation of Ceritinib and amorphous form of Ceritinib |
| JP2019196359A (ja) * | 2019-06-17 | 2019-11-14 | ノバルティス アーゲー | ピリミジン誘導体およびそれらの中間体を調製する化学的方法 |
| GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
| EP4092021B1 (en) * | 2020-01-17 | 2025-11-12 | Xuanzhu Biopharmaceutical Co., Ltd. | Crystal form of polycyclic anaplastic lymphoma kinase inhibitor |
| MX2022011768A (es) * | 2020-03-30 | 2022-10-18 | Jiangsu Yahong Meditech Co Ltd | Forma cristalina del profarmaco de nitroxolina, la composicion farmaceutica que la contiene, y el metodo de preparacion y aplicacion de la misma. |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| WO2025034702A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Rmc-6291 for use in the treatment of ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| PL2287156T3 (pl) * | 2003-08-15 | 2013-11-29 | Novartis Ag | 2,4-Di(fenyloamino)-pirymidyny stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| CN101616895A (zh) | 2006-12-08 | 2009-12-30 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| PL2091918T3 (pl) * | 2006-12-08 | 2015-02-27 | Novartis Ag | Związki i kompozycje jako inhibitory kinazy białkowej |
| MX2010002336A (es) * | 2007-08-28 | 2010-03-25 | Irm Llc | Derivados de 2-bifenil-amino-4-amino-pirimidina como inhibidores de cinasa. |
| WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| CA2720946C (en) * | 2008-04-07 | 2013-05-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| AU2009248923B2 (en) * | 2008-05-21 | 2015-01-29 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| CA2763717A1 (en) * | 2009-06-10 | 2010-12-16 | Cellzome Limited | Pyrimidine derivatives as zap-70 inhibitors |
| TWI481607B (zh) | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| RS57771B1 (sr) | 2010-12-17 | 2018-12-31 | Novartis Ag | Kristalni oblici 5-hloro-n2-(2-izopropoksi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina |
| CN103384470A (zh) | 2010-12-17 | 2013-11-06 | 纳幕尔杜邦公司 | 杀真菌偶氮环酰胺 |
| ME02973B (me) | 2010-12-17 | 2018-07-20 | Reata Pharmaceuticals Inc | Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije |
| CN105294650A (zh) | 2014-08-01 | 2016-02-03 | 江苏奥赛康药业股份有限公司 | 一种Ceritinib化合物及其药物组合物 |
| WO2016081538A1 (en) | 2014-11-18 | 2016-05-26 | Teva Pharmaceuticals International Gmbh | Solid state forms of ceritinib and salts thereof |
| US9566882B2 (en) | 2014-11-21 | 2017-02-14 | Tk Holdings Inc. | Airbag module |
| CN105622577A (zh) | 2014-11-29 | 2016-06-01 | 江苏先声药业有限公司 | 一种色瑞替尼的新晶型及其制备方法 |
| MX2017007097A (es) | 2014-12-04 | 2017-09-05 | Bristol Myers Squibb Co | Combinacion de anticuerpos anti-cs1 y anti-muerte programada 1 (pd1) para tratar cancer (mieloma). |
| WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
| EP3328848A1 (en) | 2015-07-28 | 2018-06-06 | Zentiva, K.S. | Solid forms of ceritinib free base |
| CN105061397B (zh) | 2015-08-07 | 2018-01-02 | 武汉英普瑞医药科技有限公司 | 一种色瑞替尼的c型晶型及其制备方法与应用 |
-
2011
- 2011-12-15 RS RS20181240A patent/RS57771B1/sr unknown
- 2011-12-15 JP JP2013544762A patent/JP5916752B2/ja active Active
- 2011-12-15 PH PH1/2013/501254A patent/PH12013501254A1/en unknown
- 2011-12-15 MY MYPI2016001551A patent/MY177742A/en unknown
- 2011-12-15 CN CN202011050061.0A patent/CN112125884A/zh active Pending
- 2011-12-15 AR ARP110104703A patent/AR084309A1/es not_active Application Discontinuation
- 2011-12-15 EP EP18186197.2A patent/EP3453708B8/en active Active
- 2011-12-15 CN CN201710063793.5A patent/CN107056751A/zh active Pending
- 2011-12-15 PT PT16167355T patent/PT3121171T/pt unknown
- 2011-12-15 CA CA2821102A patent/CA2821102C/en active Active
- 2011-12-15 PL PL11806079T patent/PL2651918T3/pl unknown
- 2011-12-15 NZ NZ610713A patent/NZ610713A/en not_active IP Right Cessation
- 2011-12-15 CN CN201710063792.0A patent/CN106831716A/zh active Pending
- 2011-12-15 CN CN201180060435XA patent/CN103282359A/zh active Pending
- 2011-12-15 KR KR1020197005138A patent/KR20190022903A/ko not_active Ceased
- 2011-12-15 ES ES16167355T patent/ES2696526T3/es active Active
- 2011-12-15 SG SG10201510082XA patent/SG10201510082XA/en unknown
- 2011-12-15 RU RU2016136823A patent/RU2746159C2/ru active
- 2011-12-15 CN CN201410457562.9A patent/CN104262324A/zh active Pending
- 2011-12-15 KR KR1020187007996A patent/KR20180032680A/ko not_active Ceased
- 2011-12-15 US US13/993,217 patent/US9309229B2/en active Active
- 2011-12-15 SI SI201131583T patent/SI3121171T1/sl unknown
- 2011-12-15 HU HUE16167355A patent/HUE041845T2/hu unknown
- 2011-12-15 DK DK16167355.3T patent/DK3121171T3/en active
- 2011-12-15 HR HRP20171477TT patent/HRP20171477T1/hr unknown
- 2011-12-15 PL PL16167355T patent/PL3121171T3/pl unknown
- 2011-12-15 EP EP11806079.7A patent/EP2651918B1/en not_active Revoked
- 2011-12-15 EP EP16167355.3A patent/EP3121171B1/en active Active
- 2011-12-15 MX MX2013006952A patent/MX338210B/es active IP Right Grant
- 2011-12-15 WO PCT/US2011/065030 patent/WO2012082972A1/en not_active Ceased
- 2011-12-15 CN CN202210792464.5A patent/CN114989139A/zh active Pending
- 2011-12-15 PE PE2013001425A patent/PE20140698A1/es not_active Application Discontinuation
- 2011-12-15 LT LTEP16167355.3T patent/LT3121171T/lt unknown
- 2011-12-15 CN CN201610217386.0A patent/CN106008462A/zh active Pending
- 2011-12-15 KR KR1020207009828A patent/KR102325775B1/ko active Active
- 2011-12-15 BR BR112013015000A patent/BR112013015000A2/pt not_active Application Discontinuation
- 2011-12-15 LT LTEP11806079.7T patent/LT2651918T/lt unknown
- 2011-12-15 RU RU2013132947A patent/RU2599785C3/ru active Protection Beyond IP Right Term
- 2011-12-15 MY MYPI2013001848A patent/MY164810A/en unknown
- 2011-12-15 SG SG2013039342A patent/SG190856A1/en unknown
- 2011-12-15 ES ES11806079.7T patent/ES2643016T3/es active Active
- 2011-12-15 ES ES18186197T patent/ES2905973T3/es active Active
- 2011-12-15 KR KR1020137018605A patent/KR20130130022A/ko not_active Withdrawn
- 2011-12-15 SI SI201131289T patent/SI2651918T1/sl unknown
- 2011-12-15 AU AU2011343775A patent/AU2011343775B2/en active Active
- 2011-12-15 PT PT118060797T patent/PT2651918T/pt unknown
- 2011-12-15 DK DK11806079.7T patent/DK2651918T3/en active
- 2011-12-16 TW TW100146987A patent/TWI576343B/zh active
- 2011-12-16 TW TW105112710A patent/TWI576344B/zh active
-
2013
- 2013-05-17 ZA ZA2013/03599A patent/ZA201303599B/en unknown
- 2013-05-17 TN TNP2013000216A patent/TN2013000216A1/fr unknown
- 2013-05-20 IL IL226474A patent/IL226474A/en active IP Right Grant
- 2013-06-14 CL CL2013001723A patent/CL2013001723A1/es unknown
- 2013-06-17 GT GT201300153A patent/GT201300153A/es unknown
- 2013-06-28 MA MA36066A patent/MA34771B1/fr unknown
- 2013-07-04 CO CO13158446A patent/CO6801792A2/es not_active Application Discontinuation
- 2013-07-16 EC ECSP13012770 patent/ECSP13012770A/es unknown
-
2016
- 2016-03-02 US US15/058,489 patent/US20160175305A1/en not_active Abandoned
-
2017
- 2017-10-11 CY CY20171101064T patent/CY1119474T1/el unknown
-
2018
- 2018-10-22 HR HRP20181737TT patent/HRP20181737T1/hr unknown
- 2018-11-09 CY CY181101192T patent/CY1121017T1/el unknown
-
2021
- 2021-03-19 AR ARP210100698A patent/AR122395A2/es not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GT201300153A (es) | Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina | |
| UY35467A (es) | Compuestos orgánicos | |
| ECSP17081744A (es) | Nuevos derivados hidroxiéster,un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CR20140106A (es) | Compuestos y composiciones como inhibidores de la quinasa c-kit | |
| CR20140275A (es) | Triazolopiridinas sustituidas | |
| GT201400144A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| ECSP16005566A (es) | Sulfonamidas como moduladores de canales de sodio | |
| DOP2017000101A (es) | Formas cristalinas de 5-cloro-n4-[2-(dimetilfosforil)fenil]-n2-{2-metoxi-4-[4-(4-metilpiperazin-1-il)piperidin-1-il]pirimidina-2,4-diamina | |
| UY35485A (es) | Compuestos heterocíclicos y usos de los mismos | |
| CR20170077A (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| NI201300080A (es) | Formas sólidas de 3 - ( 5 - amino - 2 - metil - 4 - oxo - 4h - quinazolin - 3 - il ) - piperidin - 2, 6 - diona, y sus composiciones farmacéuticas y usos | |
| UY34210A (es) | Composiciones, métodos y sistemas para la micropropagación de plantas | |
| CR20150549A (es) | Compuestos heterocíclicos y sus usos | |
| CL2016001367A1 (es) | Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015). | |
| MX338078B (es) | Cristales de anticuerpos anti-esclerostina y formulaciones de los mismos. | |
| CO6940429A2 (es) | Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación | |
| CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| SV2018005760A (es) | Derivados de aminotiazol utiles como agentes antiviricos | |
| MX2017007377A (es) | Compuestos organicos. | |
| CL2014002986A1 (es) | Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k. | |
| NI201400042A (es) | 2 - tiopirimidinonas | |
| UY34169A (es) | ?compuestos heterociclicos microbiocidas,composiciones que los contienen, y métodos para controlar o prevenir la infestación de plantas | |
| PE20150167A1 (es) | (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel | |
| DK2550922T3 (da) | Tibiaimplantat til stramning af knæskalsledbåndene |